fbpx Janssen Digital Solutions QuickFire Challenge Awardees Recognized at AI4Health Event - News | JLABS

Janssen Digital Solutions QuickFire Challenge Awardees Recognized at AI4Health Event

December 9, 2020 -
4 months ago
Other news

December 9, 2020—  Janssen Pharmaceutica NV, facilitated by Johnson & Johnson Innovation, together with the Paris Brain Institute (“ICM”); is proud to announce the awardees in the Janssen Digital Solutions QuickFire Challenge: AgenT, biotx.ai, Hyfe, iLoF – Intelligent Lab on Fiber, and Sentio Solutions. The challenge invited EMEA-based companies to submit technologies and solutions with the potential to scale for impact across EMEA within the next five years. 

AgenT

AgenT

AgenT is a life sciences company whose mission is to detect Alzheimer’s early through a simple blood test. By combining multiomics assays with advanced machine learning techniques to recognize Alzheimer’s associated patterns, AgenT aims to develop the first blood test to detect Alzheimer’s up to 20 years before the dementia onset.

Bio tx

biotx.ai

biotx.ai developed its technology for the analysis of wide genomic data with the aim to solve the missing heritability problem of complex diseases for better diagnostics and new therapeutics.

Hyfe

Hyfe

Hyfe builds acoustic AI diagnostics tools that run on any smartphone as well as on dedicated devices and wearables. Since entering the market in April 2020, Hyfe has been detecting coughs from ambient sound and tracking them over space and time.

iLoF

iLoF – Intelligent Lab on Fiber

iLoF is working to enable a new era of personalized medicine by using AI and photonics with the aim to build a cloud-based library of disease biomarkers and biological profiles. It aims to provide screening and stratification tools in an affordable, fast, and portable way, helping to save the cost and time spent screening for clinical trials.

Sentio

Sentio Solutions

Sentio Solutions develops biomarkers and digital therapeutics with the aim to change the way we diagnose, manage, and care for mental health. The company’s premier offering, Feel, combines its proprietary Feel Emotion Sensor with evidence-based techniques. Together they aim to help people notice, accept, and embrace their emotions with the goal to change the way they think and behave. The company is also offering the Feel Relief Program, a tailored and structured mental health program aiming to meet the demand and need for emotional help during the COVID-19 pandemic.

The awardees will receive residency at the iPEPS incubator for nine months — inclusive of support that aims to help health tech startups accelerate their growth and reach scale across EMEA — as well as mentoring and coaching from Janssen, with access to commercial expertise and connections.

The QuickFire Challenges are managed by Johnson & Johnson Innovation—JLABS, with the goal to address today’s greatest health care challenges.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.

About iPEPS

Located in Paris, in the heart of the Pitié-Salpétrière hospital, one of Europe’s largest, and at STATION F, Europe’s biggest startup campus, iPEPS - The Healthtech Hub is the Paris Brain Institute startup incubator dedicated to the development of healthcare startups.

With a network of over 700 researchers/clinicians, a clinical investigation center, a living lab and 10 state-of-the-art technological platforms, iPEPS benefits from top technical expertise and offers a unique and ideal environment for the development of breakthrough projects in medtech, biotech and digital health.

About Johnson & Johnson Innovation 

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our business development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools and resources needed to help life science startups thrive. A Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. For more information about Johnson & Johnson Innovation, please visit: www.jnjinnovation.com.

About Johnson & Johnson Innovation – JLABS

Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS, we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science called QuickFire Challenges. For more information, visit www.jlabs.jnjinnovation.com or follow @JLABS.


Related content